Sutro Biopharma (STRO) Stock Forecast, Price Target & Predictions
STRO Stock Forecast
Sutro Biopharma stock forecast is as follows: an average price target of $11.14 (represents a 201.90% upside from STRO’s last price of $3.69) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
STRO Price Target
The average price target for Sutro Biopharma (STRO) is $11.14 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $8.00. This represents a potential 201.90% upside from STRO's last price of $3.69.
STRO Analyst Ratings
According to 7 Wall Street analysts, Sutro Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for STRO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sutro Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | Tazeen Ahmad | Bank of America Securities | $12.00 | $3.60 | 232.87% | 225.20% |
| Oct 11, 2024 | Andrew Fein | H.C. Wainwright | $12.00 | $3.61 | 232.41% | 225.20% |
| Aug 16, 2024 | Asthika Goonewardene | Truist Financial | $15.00 | $4.21 | 256.29% | 306.50% |
| May 14, 2024 | James Shin | Deutsche Bank | $10.00 | $4.34 | 130.41% | 171.00% |
| May 14, 2024 | David Nierengarten | Wedbush | $8.00 | $4.23 | 89.13% | 116.80% |
| Apr 03, 2024 | Jay Olson | Oppenheimer | $10.00 | $5.09 | 96.46% | 171.00% |
| Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $11.00 | $5.09 | 116.11% | 198.10% |
| Apr 02, 2024 | Asthika Goonewardene | Truist Financial | $18.00 | $5.09 | 253.63% | 387.80% |
| Jan 13, 2023 | - | Truist Financial | $25.00 | $8.13 | 207.31% | 577.51% |
| Jan 10, 2023 | - | Piper Sandler | $18.00 | $8.29 | 117.13% | 387.80% |
The latest Sutro Biopharma stock forecast, released on Oct 11, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $12.00, which represents a 232.87% increase from the stock price at the time of the forecast ($3.60), and a 225.20% increase from STRO last price ($3.69).
Sutro Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 8 |
| Avg Price Target | $12.00 | $13.00 | $12.00 |
| Last Closing Price | $3.69 | $3.69 | $3.69 |
| Upside/Downside | 225.20% | 252.30% | 225.20% |
In the current month, the average price target of Sutro Biopharma stock is $12.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 225.20% increase as opposed to Sutro Biopharma's last price of $3.69. This month's average price target is down -7.69% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Oct 11, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Oct 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 11, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 16, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Sutro Biopharma's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave STRO a "Underperform" rating, the same as its previous rate.
Sutro Biopharma Financial Forecast
Sutro Biopharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $113.72M | $16.92M | $10.41M | $12.67M | $8.63M | $25.15M | $28.10M | $5.90M | $10.65M | $8.52M | $28.05M | $14.66M | $8.28M | $17.82M | $9.47M | $7.15M | $11.30M | $12.28M |
| Avg Forecast | $9.01M | $1.63M | $49.37M | $45.50M | $10.13M | $12.53M | $12.43M | $12.32M | $16.11M | $15.29M | $21.02M | $12.07M | $57.36M | $13.01M | $12.56M | $12.13M | $14.52M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| High Forecast | $9.01M | $1.63M | $49.37M | $45.50M | $10.13M | $12.53M | $12.43M | $12.32M | $16.11M | $23.77M | $21.02M | $12.07M | $83.82M | $13.20M | $12.56M | $12.13M | $14.52M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| Low Forecast | $9.01M | $1.63M | $49.37M | $45.50M | $10.13M | $12.53M | $12.43M | $12.32M | $16.11M | $2.57M | $21.02M | $12.07M | $28.30M | $12.81M | $12.56M | $12.13M | $14.52M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.98% | 1.30% | 0.83% | 1.04% | 0.59% | 0.70% | 1.76% | 0.56% | 0.90% | 0.95% | 2.11% | 3.05% | 1.00% | 2.45% | 1.36% | 0.67% | 1.14% | 1.25% |
Sutro Biopharma's average Quarter revenue forecast for Mar 24 based on 4 analysts is $12.07M, with a low forecast of $12.07M, and a high forecast of $12.07M. STRO's average Quarter revenue forecast represents a -89.38% decrease compared to the company's last Quarter revenue of $113.72M (Dec 23).
Sutro Biopharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $44.88M | $-44.01M | $-46.18M | $-39.68M | $-45.57M | $-18.76M | $-17.79M | $-37.69M | $-36.81M | $-28.96M | $-4.18M | $-28.21M | $-60.62M | $20.42M | $33.89M | $-17.44M | $-13.57M | $-10.54M |
| Avg Forecast | $-8.17M | $-1.47M | $-44.79M | $-41.28M | $-9.19M | $-11.36M | $-11.27M | $-11.18M | $-14.61M | $-13.87M | $-19.07M | $-41.46M | $-52.04M | $-11.80M | $-11.39M | $-37.69M | $-32.28M | $-32.40M | $-14.52M | $-34.26M | $-10.72M | $-8.14M | $-12.06M | $-25.39M | $-7.50M | $-6.61M | $-6.32M | $-13.65M | $-9.03M | $-8.94M |
| High Forecast | $-8.17M | $-1.47M | $-44.79M | $-41.28M | $-9.19M | $-11.36M | $-11.27M | $-11.18M | $-14.61M | $-2.33M | $-19.07M | $-33.17M | $-25.68M | $-11.62M | $-11.39M | $-30.15M | $-25.82M | $-32.40M | $-14.52M | $-27.41M | $-10.72M | $-8.14M | $-12.06M | $-20.31M | $-7.50M | $-6.61M | $-6.32M | $-10.92M | $-9.03M | $-8.94M |
| Low Forecast | $-8.17M | $-1.47M | $-44.79M | $-41.28M | $-9.19M | $-11.36M | $-11.27M | $-11.18M | $-14.61M | $-21.56M | $-19.07M | $-49.75M | $-76.05M | $-11.98M | $-11.39M | $-45.23M | $-38.73M | $-32.40M | $-14.52M | $-41.12M | $-10.72M | $-8.14M | $-12.06M | $-30.47M | $-7.50M | $-6.61M | $-6.32M | $-16.38M | $-9.03M | $-8.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.86% | 3.73% | 4.05% | 1.05% | 1.41% | 0.58% | 1.22% | 1.10% | 3.43% | 3.56% | 0.35% | 1.11% | 8.08% | -3.09% | -5.37% | 1.28% | 1.50% | 1.18% |
4 analysts predict STRO's average Quarter EBITDA for Mar 24 to be $-41.46M, with a high of $-33.17M and a low of $-49.75M. This is -192.37% lower than Sutro Biopharma's previous annual EBITDA (Dec 23) of $44.88M.
Sutro Biopharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $31.07M | $-49.28M | $-38.52M | $-50.05M | $-37.09M | $-17.77M | $-26.01M | $-39.09M | $-38.13M | $-30.90M | $-6.15M | $-30.36M | $-59.54M | $17.14M | $29.87M | $-19.59M | $-14.79M | $-12.91M |
| Avg Forecast | $-55.05M | $-57.61M | $-56.49M | $-62.65M | $-76.12M | $-63.64M | $-63.83M | $-66.67M | $-60.41M | $-59.67M | $-64.30M | $-44.33M | $-22.03M | $-59.78M | $-59.50M | $-40.30M | $-33.43M | $-23.45M | $-52.33M | $-36.63M | $-61.66M | $-52.90M | $-33.62M | $-27.32M | $-46.30M | $-41.19M | $-52.29M | $-15.34M | $-56.38M | $-51.31M |
| High Forecast | $-55.05M | $-57.61M | $-56.49M | $-62.65M | $-76.12M | $-63.64M | $-63.83M | $-66.67M | $-60.41M | $-43.54M | $-64.30M | $-35.46M | $-16.93M | $-59.78M | $-59.50M | $-32.24M | $-26.74M | $-23.45M | $-52.33M | $-29.31M | $-61.66M | $-52.90M | $-33.62M | $-21.86M | $-46.30M | $-41.19M | $-52.29M | $-12.27M | $-56.38M | $-51.31M |
| Low Forecast | $-55.05M | $-57.61M | $-56.49M | $-62.65M | $-76.12M | $-63.64M | $-63.83M | $-66.67M | $-60.41M | $-71.76M | $-64.30M | $-53.19M | $-25.26M | $-59.78M | $-59.50M | $-48.36M | $-40.11M | $-23.45M | $-52.33M | $-43.96M | $-61.66M | $-52.90M | $-33.62M | $-32.79M | $-46.30M | $-41.19M | $-52.29M | $-18.40M | $-56.38M | $-51.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.41% | 0.82% | 0.65% | 1.24% | 1.11% | 0.76% | 0.50% | 1.07% | 0.62% | 0.58% | 0.18% | 1.11% | 1.29% | -0.42% | -0.57% | 1.28% | 0.26% | 0.25% |
Sutro Biopharma's average Quarter net income forecast for Mar 24 is $-44.33M, with a range of $-53.19M to $-35.46M. STRO's average Quarter net income forecast represents a -242.69% decrease compared to the company's last Quarter net income of $31.07M (Dec 23).
Sutro Biopharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.07M | $15.27M | $15.00M | $15.51M | $14.72M | $14.64M | $15.14M | $15.04M | $15.76M | $16.59M | $12.54M | $11.11M | $10.38M | $9.08M | $8.64M | $8.71M | $8.70M | $8.12M |
| Avg Forecast | $6.79M | $1.23M | $37.23M | $34.32M | $7.64M | $9.45M | $9.37M | $9.30M | $12.15M | $11.53M | $15.86M | $9.11M | $43.26M | $9.81M | $9.47M | $9.15M | $13.82M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $6.82M | $7.51M | $7.43M |
| High Forecast | $6.79M | $1.23M | $37.23M | $34.32M | $7.64M | $9.45M | $9.37M | $9.30M | $12.15M | $17.92M | $15.86M | $9.11M | $63.21M | $9.96M | $9.47M | $9.15M | $16.59M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $8.18M | $7.51M | $7.43M |
| Low Forecast | $6.79M | $1.23M | $37.23M | $34.32M | $7.64M | $9.45M | $9.37M | $9.30M | $12.15M | $1.94M | $15.85M | $9.10M | $21.34M | $9.66M | $9.47M | $9.15M | $11.06M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $5.46M | $7.51M | $7.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.35% | 1.56% | 1.58% | 1.70% | 1.06% | 0.54% | 1.25% | 1.91% | 1.77% | 2.45% | 1.25% | 3.07% | 1.66% | 1.65% | 1.65% | 1.28% | 1.16% | 1.09% |
Sutro Biopharma's average Quarter SG&A projection for Mar 24 is $9.11M, based on 4 Wall Street analysts, with a range of $9.10M to $9.11M. The forecast indicates a -39.59% fall compared to STRO last annual SG&A of $15.07M (Dec 23).
Sutro Biopharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.51 | $-0.81 | $-0.00 | $-0.85 | $-0.73 | $-0.34 | $-0.55 | $-0.84 | $-0.83 | $-0.67 | $-0.13 | $-0.66 | $-1.61 | $0.46 | $1.00 | $-0.84 | $-0.64 | $-0.56 |
| Avg Forecast | $-0.68 | $-0.71 | $-0.70 | $-0.77 | $-0.94 | $-0.78 | $-0.79 | $-0.82 | $-0.74 | $-0.73 | $-0.79 | $-0.92 | $-0.27 | $-0.74 | $-0.73 | $-0.78 | $-0.62 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| High Forecast | $-0.68 | $-0.71 | $-0.70 | $-0.77 | $-0.94 | $-0.78 | $-0.79 | $-0.82 | $-0.74 | $-0.54 | $-0.79 | $-0.92 | $-0.21 | $-0.74 | $-0.73 | $-0.78 | $-0.62 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| Low Forecast | $-0.68 | $-0.71 | $-0.70 | $-0.77 | $-0.94 | $-0.78 | $-0.79 | $-0.82 | $-0.74 | $-0.88 | $-0.79 | $-0.92 | $-0.31 | $-0.74 | $-0.73 | $-0.78 | $-0.62 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.88% | 1.10% | 0.00% | 1.08% | 1.18% | 1.18% | 0.85% | 1.11% | 1.09% | 1.03% | 0.31% | 1.06% | 2.83% | -0.91% | -1.55% | 1.22% | 0.92% | 0.89% |
According to 4 Wall Street analysts, Sutro Biopharma's projected average Quarter EPS for Mar 24 is $-0.92, with a low estimate of $-0.92 and a high estimate of $-0.92. This represents a -280.70% decrease compared to STRO previous annual EPS of $0.51 (Dec 23).
Sutro Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| ANAB | AnaptysBio | $19.94 | $52.33 | 162.44% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| IDYA | IDEAYA Biosciences | $30.00 | $48.36 | 61.20% | Buy |
| MGTX | MeiraGTx | $5.96 | $9.00 | 51.01% | Buy |
| MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
STRO Forecast FAQ
Is Sutro Biopharma a good buy?
Yes, according to 7 Wall Street analysts, Sutro Biopharma (STRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of STRO's total ratings.
What is STRO's price target?
Sutro Biopharma (STRO) average price target is $11.14 with a range of $8 to $15, implying a 201.90% from its last price of $3.69. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sutro Biopharma stock go up soon?
According to Wall Street analysts' prediction for STRO stock, the company can go up by 201.90% (from the last price of $3.69 to the average price target of $11.14), up by 306.50% based on the highest stock price target, and up by 116.80% based on the lowest stock price target.
Can Sutro Biopharma stock reach $6?
STRO's average twelve months analyst stock price target of $11.14 supports the claim that Sutro Biopharma can reach $6 in the near future.
What is Sutro Biopharma's current price target trend?
2 Wall Street analysts forecast a $12 price target for Sutro Biopharma (STRO) this month, up 225.20% from its last price of $3.69. Compared to the last 3 and 12 months, the average price target increased by 252.30% and increased by 225.20%, respectively.
What are Sutro Biopharma's analysts' financial forecasts?
Sutro Biopharma's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $47.4M (high $47.4M, low $47.4M), average EBITDA is $-43.005M (high $-43.005M, low $-43.005M), average net income is $-270M (high $-270M, low $-270M), average SG&A $35.75M (high $35.75M, low $35.75M), and average EPS is $-3.327 (high $-3.327, low $-3.327). STRO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $105.5M (high $105.5M, low $105.5M), average EBITDA is $-95.721M (high $-95.721M, low $-95.721M), average net income is $-232M (high $-232M, low $-232M), average SG&A $79.57M (high $79.57M, low $79.57M), and average EPS is $-2.854 (high $-2.854, low $-2.854).
Did the STRO's actual financial results beat the analysts' financial forecasts?
Based on Sutro Biopharma's last annual report (Dec 2023), the company's revenue was $153.73M, beating the average analysts forecast of $95.05M by 61.74%. Apple's EBITDA was $-89.278M, missing the average prediction of $-113M by -20.94%. The company's net income was $-107M, missing the average estimation of $-182M by -41.20%. Apple's SG&A was $62.58M, missing the average forecast of $71.68M by -12.69%. Lastly, the company's EPS was $-0.0018, missing the average prediction of $-2.524 by -99.93%. In terms of the last quarterly report (Dec 2023), Sutro Biopharma's revenue was $113.72M, beating the average analysts' forecast of $57.36M by 98.27%. The company's EBITDA was $44.88M, missing the average prediction of $-52.039M by -186.25%. Sutro Biopharma's net income was $31.06M, missing the average estimation of $-22.033M by -240.99%. The company's SG&A was $15.07M, missing the average forecast of $43.26M by -65.15%. Lastly, the company's EPS was $0.51, missing the average prediction of $-0.271 by -288.01%